---
title: "Alumis Q2 FY26 net loss widens to $142.22 million; revenue falls 37.65% to $1.66 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295838247.md"
description: "Alumis reported a widened Q2 FY26 net loss of $142.2 million, reversing prior year profits, as revenue dropped 37.65% to $1.66 million due to lower collaboration income. R&D and G&A expenses decreased significantly. The period included a $41.82 million impairment for the lonigutamab program. The company holds $502.3 million in cash, projecting runway into Q4 2027, with a psoriasis NDA planned for late 2026."
datetime: "2026-08-13T20:01:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295838247.md)
  - [en](https://longbridge.com/en/news/295838247.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295838247.md)
---

# Alumis Q2 FY26 net loss widens to $142.22 million; revenue falls 37.65% to $1.66 million

-   Alumis posted a net loss of $142.2 million for Q2 2026, swinging from net income of $59.3 million a year earlier. \* Revenue fell 37.65% to $1.66 million, reflecting lower collaboration revenue tied to the Kaken licensing agreement. \* Research and development expense declined 21.53% to $85.34 million, while general and administrative costs dropped 32.2% to $23.36 million. \* Operating expenses included a $41.82 million impairment tied to the lonigutamab program, following a decision to pursue strategic alternatives. \* Cash, cash equivalents and marketable securities totaled $502.3 million; runway forecast into Q4 2027, with a psoriasis NDA planned for Q4 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131601PRIMZONEFULLFEED9809581) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ALMS.US](https://longbridge.com/en/quote/ALMS.US.md)
- [4521.JP](https://longbridge.com/en/quote/4521.JP.md)

## Related News & Research

- [Alumis says envudeucitinib hits 54% PASI 100 at 48 weeks in ONWARD3 plaque psoriasis extension study](https://longbridge.com/en/news/295445123.md)
- [Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates](https://longbridge.com/en/news/295548881.md)
- [Jacktel to webcast Q2, H1 2026 results](https://longbridge.com/en/news/296198778.md)
- [Tobii schedules Q2 2026 interim report webcast presentation](https://longbridge.com/en/news/296061914.md)
- [Flexsteel Q4 2026 Earnings Preview](https://longbridge.com/en/news/296031749.md)